Company retains an influential clinician for the launch of its innovative software for the diagnostic of Parkinson’s Disease.
GAINESVILLE, FL – neuropacsTM, a leading innovator in AI-driven neurological diagnostics, today announced that David K. Simon, MD, PhD, has accepted to serve on neuropacs’ Board of Clinical Advisors.
“Dr. Simon brings cutting-edge clinical expertise to neuropacs” stated Dr. Martin Handfield, neuropacs’ President and CEO. He added:” Dr. Simon is well respected in the Parkinson’s community and he has experience in both the clinic and in the development of novel therapeutics modalities, which will bring unique skillsets to the Company. He has completed the Harvard-Longwood Neurology Residency in Boston, followed by a Movement Disorders Fellowship at Massachusetts General Hospital. He then joined the faculty at Beth Israel Deaconess Medical Center and Harvard Medical School where he is now a Professor of Neurology and Chief of the Movement Disorders Division. His participation in several clinical studies to test agents that may have protective effects in Parkinson’s disease and related disorders, and his experience with heading a laboratory for developing novel strategies for neuroprotection in Parkinson’s disease, will prove instrumental for neuropacs. Dr Simon served as a member of the NIH Molecular Neurogenetics study section. He is currently Chair of the Scientific Advisory Board for the Weston Brain Institute, as well as Chair of the Cure Parkinson’s International Linked Clinical Trials Committee, and has received additional research funding from the American Federation for Aging Research, National Parkinson Foundation, Michael J. Fox Foundation, and the NINDS”, Handfield concluded.
Dr. Simon commented: ” I’m thrilled with the opportunity to interface with neuropacs’ Founders and their Management Team, and I believe that neuropacs’ novel diagnostic tool has the potential to change how several neurodegenerative diseases will soon be diagnosed, ultimately enabling earlier interventions, better patient stratification in clinical trials and improved patient outcomes.”
For more information about neuropacsTM and its revolutionary diagnostic solutions, visit neuropacs.com.
About neuropacsTM:
neuropacsTM is a pioneering neurological technology company dedicated to developing innovative AI-driven diagnostics. With a commitment to advancing healthcare through cutting-edge technologies, neuropacsTM remains at the forefront of revolutionizing clinical care standards.
Forward-Looking Statements
This communication includes express and implied “forward-looking statements.” Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. By their nature, these statements are subject to numerous risks and uncertainties, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, any future presentations, or otherwise, except as required by applicable law.